ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Psychiatry

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,550Medicare Part D Prescriptions Filled, Including Refills

Rank: 16 out of 154

$830K Total Retail Price of All Prescriptions

Rank: 24 out of 154

502 Patients Receiving at Least One Drug in Part D
28%Patients 65 Years and Older
64% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Alabama
Lower avg

Schedule Two
Controlled Substances

13% of this provider’s 502 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

7% of this provider’s 502 patients filled at least one prescription for a schedule three drug, compared to an average of 2%.

Risky Drugs to Seniors

5% of this provider’s 2,256 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 3%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$97 was the average price of a prescription from this provider, compared to $130 among peers.

Prescriptions per Patient

17 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Alabama
ZOLPIDEM TARTRATE 501 64 1 8
TRAZODONE HCL 416 106 2 1
MIRTAZAPINE 288 119 3 11
FLUOXETINE HCL 270 17 4 6
LAMOTRIGINE 260 11 5 9
CYMBALTA 216 41 6 12
BUPROPION HCL SR 199 52 7 31
LITHIUM CARBONATE 191 41 8 16
BUSPIRONE HCL 175 43 9 24
AMPHETAMINE SALT COMBO 173 16 S2 10 32
BENZTROPINE MESYLATE 169 36 R 11 3
QUETIAPINE FUMARATE 168 46 12 5
CITALOPRAM HBR 167 44 13 4
RISPERIDONE 155 52 14 2
OLANZAPINE 141 67 15 14
SERTRALINE HCL 135 53 16 10
BUPROPION XL 133 25 17 19
DONEPEZIL HCL 126 97 18 36
ESCITALOPRAM OXALATE 126 44 18 15
GABAPENTIN 119 23 20 20
PANTOPRAZOLE SODIUM 118 27 21 67
CHLORPROMAZINE HCL 113 15 22 48
ABILIFY 113 16 22 7
HYDROCODONE-ACETAMINOPHEN 105 30 S3 24 49
NAMENDA 98 76 25 41
DOXEPIN HCL 92 14 26 40
TOPIRAMATE 88 0 27 34
VENLAFAXINE HCL 81 21 28 54
LEVOTHYROXINE SODIUM 80 40 29 56
PRISTIQ ER 79 14 30 47
VENLAFAXINE HCL ER 77 21 31 17
TRAMADOL HCL 66 11 32 83
CLONAZEPAM 65 0 33 110
INVEGA 64 17 34 43
DIVALPROEX SODIUM ER 61 13 35 13
CLOMIPRAMINE HCL 59 41 R 36 83
SEROQUEL 58 14 37 25
AMITRIPTYLINE HCL 57 22 R 38 44
NORTRIPTYLINE HCL 57 27 38 73
SEROQUEL XR 54 0 40 26
DIVALPROEX SODIUM 53 24 41 23
CLOZAPINE 53 0 41 30
HYDROXYZINE PAMOATE 53 0 R 41 28
LOXAPINE 51 0 44 57
LISINOPRIL 50 16 45 66
ZIPRASIDONE HCL 50 0 45 18
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 2, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.